News
Avacta announces escalation in clinical study of AVA6000
Avacta – a clinical stage oncology company – has announced that the first-in-human phase 1 trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort. It follows a positive review of safety data from the dosing during the second cohort.